(UroToday.com) Beginning with the introduction of docetaxel for metastatic castration resistant prostate cancer (mCRPC) in 2004, there has been a dramatic and rapid proliferation of systemic therapy options in advanced prostate cancer. Following developments in the mCRPC disease space, many of the same treatments have now been adopted in patients with metastatic castration-sensitive disease (mCSPC). Since 2015, the addition of docetaxel, novel hormonal therapies (including abiraterone acetate, enzalutamide, and apalutamide), and local prostate-directed radiotherapy (in those with low-volume metastases) have proven benefit in patients with mCSPC. In the Prostate, Testicular, and Penile Oral Abstract Session at at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Karim Fizazi presented the first results of the PEACE-1 trial assessing the role of the combination of abiraterone acetate with prednisone and local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer. The Prostate Cancer Consortium in Europe (PEACE) is an academic, European program.